Axiota Animal Health

Axiota Animal Health is an animal health company that develops and markets biology- and prevention-based solutions for beef and dairy cattle producers. Its key product offerings include Multimin 90, a trace mineral injection that supports cattle health and reproduction, and Lactipro, a probiotic consisting of a proprietary strain of Megasphaera elsdenii (Mega e), a superior lactic acid utilizer native to the rumen. These are designed to help cattle thrive during stressful periods, ensuring better health and productivity across all stages of production.

The company operates technology centers in the US and Ireland and supplies to the US, the EU, Mexico, and Brazil.

Key customers and partnerships

In October 2022, Axiota entered an agreement with Resilient Biotics to co-develop a new treatment for bovine respiratory disease (BRD) based on Resilient Biotics' proprietary microbiome-based technology. As part of this collaboration, Axiota also invested in Resilient Biotics to develop a portfolio of novel microbiome products for the global cattle market. The companies aim to leverage Resilient Biotics' microbiome genomics and data science capabilities combined with Axiota's expertise in developing and commercializing novel microbial products through its MS Biotec Microbial Technology Center.

Funding and financials

In March 2024, the company raised USD 30 million in a private equity round backed by 34 investors, according to SEC filings.